ROP.SW
Company Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.52B | 62.40B | 60.44B | 65.81B | 62.80B | 58.32B | 63.75B | 59.50B | 55.75B | 52.64B | 50.40B | 49.87B |
| Net Income | 12.88B | 8.28B | 11.50B | 12.42B | 13.93B | 14.29B | 13.50B | 10.50B | 8.63B | 9.58B | 8.86B | 9.33B |
| EPS | 16.18 | 10.36 | 14.39 | 15.53 | 16.39 | 16.72 | 15.77 | 12.30 | 10.12 | 11.24 | 10.41 | 10.99 |
| Free Cash Flow | 14.08B | 15.09B | 11.45B | 13.34B | 16.02B | 11.47B | 18.88B | 15.94B | 14.52B | 10.86B | N/A | N/A |
| FCF / Share | 17.69 | 18.93 | 14.33 | 16.67 | 18.85 | 13.42 | 22.06 | 18.66 | 17.02 | 12.74 | N/A | N/A |
| Operating CF | 17.83B | 20.09B | 16.09B | 17.89B | 20.57B | 18.16B | 22.39B | 19.98B | 18.02B | 15.00B | N/A | N/A |
| Total Assets | 100.70B | 101.80B | 90.47B | 88.15B | 92.32B | 86.14B | 83.09B | 78.52B | 76.68B | 76.82B | N/A | N/A |
| Total Debt | 33.19B | 36.35B | 30.78B | 26.54B | 32.55B | 15.41B | 15.58B | 18.77B | 18.96B | 22.36B | N/A | N/A |
| Cash & Equiv | 5.58B | 6.97B | 5.38B | 4.99B | 6.85B | 5.73B | 6.08B | 6.68B | 4.72B | 4.16B | N/A | N/A |
| Book Value | 33.80B | 31.77B | 29.32B | 27.99B | 24.49B | 36.34B | 32.75B | 27.62B | 26.44B | 23.91B | N/A | N/A |
| Return on Equity | 0.38 | 0.26 | 0.39 | 0.44 | 0.57 | 0.39 | 0.41 | 0.38 | 0.33 | 0.40 | N/A | N/A |
| Metric | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 | Q4 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.57B | 30.94B | 31.64B | 30.76B | 28.94B | 29.78B | 30.99B | 32.30B | 32.09B | 30.71B | 29.04B | 29.28B |
| Net Income | 5.47B | 7.41B | 2.02B | 6.26B | 4.36B | 7.14B | 3.89B | 8.53B | 6.13B | 7.80B | 6.22B | 8.08B |
| EPS | 6.87 | 9.31 | 2.54 | 7.83 | 5.47 | 8.93 | 4.87 | 10.54 | 7.25 | 9.14 | 7.27 | 9.45 |
| Free Cash Flow | 9.16B | 2.71B | 9.88B | 6.19B | 5.23B | 5.61B | 6.08B | 7.26B | 10.14B | 5.88B | 7.80B | 3.67B |
| FCF / Share | 11.51 | 3.38 | 12.42 | 7.75 | 6.56 | 7.03 | 7.61 | 8.97 | 12.01 | 6.88 | 9.12 | 4.29 |
| Operating CF | 11.23B | 3.55B | 11.68B | 7.91B | 7.91B | 7.59B | 8.61B | 9.28B | 12.60B | 7.97B | 11.35B | 6.81B |
| Total Assets | 100.70B | 94.77B | 101.80B | 95.79B | 90.47B | 84.37B | 88.15B | 86.74B | 92.32B | 87.89B | 86.14B | 80.36B |
| Total Debt | 31.64B | 34.63B | 36.35B | 34.44B | 30.78B | 25.39B | 26.54B | 27.75B | 32.55B | 15.01B | 15.41B | 15.04B |
| Cash & Equiv | 5.58B | 7.55B | 6.97B | 4.82B | 5.38B | 3.72B | 4.99B | 4.32B | 6.85B | 5.00B | 5.73B | 3.77B |
| Book Value | 33.80B | 28.68B | 31.77B | 28.94B | 29.32B | 26.52B | 27.99B | 25.19B | 24.49B | 37.81B | 36.34B | 31.51B |
| Return on Equity | 0.16 | 0.26 | 0.06 | 0.22 | 0.15 | 0.27 | 0.14 | 0.34 | 0.25 | 0.21 | 0.17 | 0.26 |